News | Heart Failure | November 02, 2015

Cardionomic Raises $20 Million to Develop Neuromodulation for Heart Failure

Therapy tackles the root cause of acute decompensated heart failure to reduce readmissions

November 2, 2015 — Medical device developer Cardionomic Inc. announced that it has received $20 million in Series A financing. Investors include New Enterprise Associates (NEA), the Cleveland Clinic, Greatbatch Inc. and others.

The company will use the funding to continue development of an innovative neuromodulation therapy for acute decompensated heart failure (ADHF), a condition in which patients with heart failure experience fluid accumulation in their lungs and other tissues, making it difficult for them to breathe, sleep and function.

ADHF leads to more than 1 million U.S. hospital admissions and to healthcare costs exceeding $10 billion annually, according to the American Heart Association (AHA). Furthermore, nearly one-quarter of ADHF patients are readmitted to the hospital within one month of treatment and half are re-hospitalized within six months. With hospitals facing financial penalties for readmissions within 30 days, the high rate of re-hospitalization of ADHF patients is a growing concern.

“Current ADHF approaches, all of which use drug therapies, inadequately treat the condition and have not improved over the past decades,” said William T. Abraham, M.D., Cardionomic’s chief medical officer and one of the world’s leading heart failure physicians. “The Cardionomic therapy targets the primary cause of worsening heart failure, namely decreased myocardial contractility.” Increased contractility improves the heart’s pumping performance.

Cardionomic’s therapy selectively stimulates cardiac nerve branches, which safely improves contractility and addresses the disorder’s root cause instead of focusing on relief of symptoms, which is the current standard of care. The therapy is expected to be delivered to the patient upon admission and to remain in place for one to three days before it is removed.

“This targeted increase in contractility rebalances hemodynamics to normalize blood flow to organs, such as the kidneys and brain, and restores kidney function to eliminate fluids. It thereby treats both the root cause of ADHF and its symptoms,” said Abraham.

For more information: www.cardionomicinc.com

Related Content

Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Overlay Init